ROR1-Targeting provides opportunities for drug modalities with enhanced effector function

BARCELONA, Spain I June17, 2022 I La Merie Publishing released today its newest report entitled “ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis”.

Orlistat is a drug that is a combination of two chemicals found in the potato. Side effects of doxycycline can include fatigue, stomach pain, dizziness and vendo viagra o cialis swelling or pain. The sponge is characterised by a large cylindrical sponginous body encased by a silky fibrous matrix of gelatinous material.

He'd been in the car for a minute or so, staring out the window, when his eyes locked on something and he looked down sharply at the road. The best online drugstores offer their customers a wide range of medications and they may be able prednisolon acis 10 mg preis Tak Bai to obtain your prescription drug online and bring it to you at the same time as a generic drug. You can burn away 1000 calories a day by eating a very low-calorie, very high-quality diet.

This report evaluates Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) from an industry perspective for its suitability as a tumor-specific target for cancer therapy based on its expression profile and preclinical and clinical safety and efficacy data of the various drug modalities employed for discovery and development of ROR1-targeted therapy candidates.

ROR1 is a compelling candidate target for effector enhanced drug modalities, e.g. antibody-drug conjugates, adoptive cell therapy with chimeric antigen receptor T-cell or natural killer (NK) cells, or with T-cell or NK cell engaging bispecific antibodies. ROR1 is expressed on the surface of many lymphatic and epithelial malignancies and has a putative role in tumor cell survival. In normal tissues, ROR1 protein is abundantly expressed during embryonic development, but absent in most adult tissues except a stage of immature B cells in the bone marrow. This differential expression of ROR1 in cancerous and normal tissue is encouraging as its promises to avoid on-target/off-tumor effects.

The report has identified the players in the field and presents a competitive landscape analysis of stakeholders and a pipeline review based on the specific profiles of drug candidates and companies active in the field. The report includes information about business transaction in the field, such as acquisitions, partnerships & collaborations and licensing deals. Furthermore, the financial background and situation of the key players is described.

What will you find in the report:

  • The scientific rationale for ROR1-targeted therapies based on target characteristics and its differential expression profile;
  • Preclinical safety of ROR1-targeted therapy candidates;
  • Clinical experience and proof-of-concept with ROR1-targeted drug modalities;
  • Clinical indications suitable for development of ROR1-targeted therapies and their patient populations;
  • The competitive landscape of ROR1-targeted drug modalities in development;
  • Specific profiles of ROR1-targeted drug modalities; and
  • Profiles of companies active in the development of anti-ROR1 therapy candidates.

The report ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis can be acquired at La Merie Publishing’s online store:

About La Merie Publishing

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store and at selected Resellers.

To leverage its expertise and knowledge accumulated in the in-house database, La Merie Publishing offers custom report preparation services for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.

SOURCE: La Merie Publishing